Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates in purine recycling and energy homeostasis but might also be crucial for averting inflammation and other forms of cellular stress during...
Saved in:
Main Authors: | Emma Rybalka (Author), Stephanie Kourakis (Author), Charles A. Bonsett (Author), Behzad Moghadaszadeh (Author), Alan H. Beggs (Author), Cara A. Timpani (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo
by: Cara A. Timpani, et al.
Published: (2023) -
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
by: Stephanie Kourakis, et al.
Published: (2020) -
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
by: Cara A. Timpani, et al.
Published: (2020) -
Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences
by: Dean G. Campelj, et al.
Published: (2022) -
Untapped potential - choose wisely
by: Catharine Anna Henderson
Published: (2015)